GSK Statistics
Total Valuation
GSK has a market cap or net worth of $98.67 billion. The enterprise value is $118.61 billion.
| Market Cap | 98.67B |
| Enterprise Value | 118.61B |
Important Dates
The last earnings date was Tuesday, July 28, 2026, before market open.
| Earnings Date | Jul 28, 2026 |
| Ex-Dividend Date | Aug 14, 2026 |
Share Statistics
GSK has 4.01 billion shares outstanding. The number of shares has decreased by -1.36% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.01B |
| Shares Change (YoY) | -1.36% |
| Shares Change (QoQ) | -0.29% |
| Owned by Insiders (%) | 0.06% |
| Owned by Institutions (%) | 86.94% |
| Float | 3.88B |
Valuation Ratios
The trailing PE ratio is 15.43 and the forward PE ratio is 9.71.
| PE Ratio | 15.43 |
| Forward PE | 9.71 |
| PS Ratio | 2.24 |
| Forward PS | 2.84 |
| PB Ratio | 4.33 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 10.57 |
| P/OCF Ratio | 8.75 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.26, with an EV/FCF ratio of 12.71.
| EV / Earnings | 18.54 |
| EV / Sales | 2.69 |
| EV / EBITDA | 8.26 |
| EV / EBIT | 9.23 |
| EV / FCF | 12.71 |
Financial Position
The company has a current ratio of 0.82, with a Debt / Equity ratio of 1.06.
| Current Ratio | 0.82 |
| Quick Ratio | 0.52 |
| Debt / Equity | 1.06 |
| Debt / EBITDA | 1.66 |
| Debt / FCF | 2.60 |
| Interest Coverage | 14.65 |
Financial Efficiency
Return on equity (ROE) is 33.38% and return on invested capital (ROIC) is 26.38%.
| Return on Equity (ROE) | 33.38% |
| Return on Assets (ROA) | 10.01% |
| Return on Invested Capital (ROIC) | 26.38% |
| Return on Capital Employed (ROCE) | 24.09% |
| Weighted Average Cost of Capital (WACC) | 5.35% |
| Revenue Per Employee | $659,077 |
| Profits Per Employee | $95,696 |
| Employee Count | 66,841 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 1.42 |
Taxes
In the past 12 months, GSK has paid $850.47 million in taxes.
| Income Tax | 850.47M |
| Effective Tax Rate | 10.86% |
Stock Price Statistics
The stock price has increased by +26.55% in the last 52 weeks. The beta is 0.30, so GSK's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | +26.55% |
| 50-Day Moving Average | 51.81 |
| 200-Day Moving Average | 51.97 |
| Relative Strength Index (RSI) | 38.27 |
| Average Volume (20 Days) | 4,328,752 |
Short Selling Information
The latest short interest is 14.52 million, so 0.73% of the outstanding shares have been sold short.
| Short Interest | 14.52M |
| Short Previous Month | 12.76M |
| Short % of Shares Out | 0.73% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.24 |
Income Statement
In the last 12 months, GSK had revenue of $44.05 billion and earned $6.40 billion in profits. Earnings per share was $3.13.
| Revenue | 44.05B |
| Gross Profit | 32.38B |
| Operating Income | 12.85B |
| Pretax Income | 7.83B |
| Net Income | 6.40B |
| EBITDA | 14.35B |
| EBIT | 12.85B |
| Earnings Per Share (EPS) | $3.13 |
Balance Sheet
The company has $4.12 billion in cash and $24.27 billion in debt, with a net cash position of -$20.15 billion or -$5.03 per share.
| Cash & Cash Equivalents | 4.12B |
| Total Debt | 24.27B |
| Net Cash | -20.15B |
| Net Cash Per Share | -$5.03 |
| Equity (Book Value) | 22.79B |
| Book Value Per Share | 5.84 |
| Working Capital | -5.27B |
Cash Flow
In the last 12 months, operating cash flow was $11.27 billion and capital expenditures -$1.94 billion, giving a free cash flow of $9.33 billion.
| Operating Cash Flow | 11.27B |
| Capital Expenditures | -1.94B |
| Depreciation & Amortization | 1.53B |
| Net Borrowing | 1.05B |
| Free Cash Flow | 9.33B |
| FCF Per Share | $2.33 |
Margins
Gross margin is 73.49%, with operating and profit margins of 29.17% and 14.52%.
| Gross Margin | 73.49% |
| Operating Margin | 29.17% |
| Pretax Margin | 17.78% |
| Profit Margin | 14.52% |
| EBITDA Margin | 32.58% |
| EBIT Margin | 29.17% |
| FCF Margin | 20.78% |
Dividends & Yields
This stock pays an annual dividend of $1.79, which amounts to a dividend yield of 3.61%.
| Dividend Per Share | $1.79 |
| Dividend Yield | 3.61% |
| Dividend Growth (YoY) | 10.38% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 57.15% |
| Buyback Yield | 1.36% |
| Shareholder Yield | 4.97% |
| Earnings Yield | 6.48% |
| FCF Yield | 9.46% |
Analyst Forecast
The average price target for GSK is $58.08, which is 17.29% higher than the current price. The consensus rating is "Hold".
| Price Target | $58.08 |
| Price Target Difference | 17.29% |
| Analyst Consensus | Hold |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 4.00% |
| EPS Growth Forecast (3Y) | 5.51% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 19, 2022. It was a reverse split with a ratio of 1:1.25.
| Last Split Date | Jul 19, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:1.25 |
Scores
GSK has an Altman Z-Score of 2.2 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.2 |
| Piotroski F-Score | 7 |